Several retrospective studies associated the drug class with lower glaucoma risk and reduced ocular hypertension incidence, while preclinical work demonstrated reduced retinal ganglion cell loss and optic nerve damage in experimental models. The experimental literature also points to inflammatory modulation, oxidative stress reduction and retinal ganglion cell survival pathways as possible mechanisms. Smaller studies evaluating IIH and DED reported reductions in intracranial pressure and improved ocular surface parameters, respectively, among treated patients. READ MORE: Blinding Disease-Weight Loss Drug Link: EMA Announces Start of Semaglutide Investigation The evidence base still has limits The review flagged recurring methodological constraints across the literature: reliance on retrospective EHR analyses and ICD-based coding, heterogeneous ocular endpoints, inconsistent imaging and limited longitudinal follow-up
GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy
LOMAIRA can help to suppress appetite, eat less, and lose weight
It mimics the function of a naturally occurring hormone in the body, GLP-1, which is released after eating a meal
Our clients consistently report feeling more vibrant, confident, and ready to accept life fully
